(Q60212683)

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Current status of platinum-based antitumor drugs

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Nucleotide cross-linking induced by photoreactions of platinum(IV)-azide complexes.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis and stereochemical characterisation of platinum(II) complexes with the antiviral agents penciclovir and famciclovir

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis of 17β-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium complexes as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Development of organometallic (organo-transition metal) pharmaceuticals

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Recent developments in the field of tumor-inhibiting metal complexes.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Metal-based antitumour drugs in the post genomic era.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

The new era in cancer research

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Mechanisms of drug inhibition of signalling molecules

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Not just research tools--proteasome inhibitors offer therapeutic promise

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

The discovery of receptor tyrosine kinases: targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Targeted therapies: a nursing perspective

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Antineoplastic and antibacterial activity of some mononuclear Ru(II) complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis and pharmacological activities of some mononuclear Ru(II) complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis, anticancer and antibacterial activity of some novel mononuclear Ru(II) complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polypyridyl complexes containing 2,6-(2'-benzimidazolyl)-pyridine/chalcone as co-ligand

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Mixed-ligand Ru(II) complexes with 2,2'-bipyridine and aryldiazo-beta-diketonato auxillary ligands: synthesis, physico-chemical study and antitumour properties

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Syntheses of ruthenium(II) quinonediimine complexes of cyclam and characterization of their DNA-binding activities and cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis, characterization, in vitro antitumor activity, DNA-binding properties and electronic structure (DFT) of the new complex cis-(Cl,Cl)[RuIICl2(NO+)(terpy)]Cl.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium complexes of analogues of the antitumor antibiotic streptonigrin

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

A highly flexible dinuclear ruthenium(II)-platinum(II) complex: crystal structure and binding to 9-ethylguanine

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis, Structure and Antitumour Properties of a New 1,2-Propylenediaminetetraacetate-Ruthenium(III) Compound

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Solution studies of the antitumor complex dichloro 1,2-propylendiaminetetraacetate ruthenium (III) and of its interactions with proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

DNA as a possible target for antitumor ruthenium(III) complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl(2)].

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Novel ruthenium complex K2[Ru(dmgly)Cl4].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Antitumour properties of dimethylsulphoxide ruthenium(II) complexes in the Lewis lung carcinoma system

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Anti-leukaemic action of RuCl2 (DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P388/DDP subline.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium (II) nitrofurylsemicarbazone complexes: new DNA binding agents

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium(II) Sulfoxide−Maltolato and −Nitroimidazole Complexes: Synthesis and MTT Assay

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Homodinuclear (Pt,Pt) and heterodinuclear (Ru,Pt) metal compounds as DNA-protein cross-linking agents: potential suicide DNA lesions

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Light-induced anticancer activity of [RuCl2(DMSO)4] complexes.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Strong Differences in the in Vitro Cytotoxicity of Three Isomeric Dichlorobis(2-phenylazopyridine)ruthenium(II) Complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2].

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L =

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Dinuclear double-stranded metallosupramolecular ruthenium complexes: potential anticancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Inhibition of cancer cell growth by ruthenium(II) arene complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

DNA Interactions of Monofunctional Organometallic Ruthenium(II) Antitumor Complexes in Cell-free Media

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium antimetastatic agents

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[{trans-RuCl4(Me2SO)}2(μ-L)] (L=ditopic, non-chelating aromatic N-ligand). A preliminary investigation

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A)

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

New Synthetic Pathways ofcis- ortrans-Hydroxytamoxifen Derivatives with in Situ Formed [Cp*Rh(solvent)3]2+Complexes: Kinetic and Thermodynamic Control, Including a Novel, Intramolecular N-π Rearrangement, and Relative Binding Affinities of the η6Co

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuCl2(clotrimazole)2.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium half-sandwich complexes bound to protein kinase Pim-1

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium complexes as protein kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Switching on a signaling pathway with an organoruthenium complex

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Ruthenium–benzocrownether complexes: Synthesis, structures, catalysis and immobilisation in ionic liquids

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Coordination chemistry of 1,3,5-triaza-7-phosphaadamantane (PTA)

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA = 1,3,5-triaza-7-phosphaadamantane).

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

In Vitro Evaluation of Rhodium and Osmium RAPTA Analogues: The Case for Organometallic Anticancer Drugs Not Based on Ruthenium

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

[Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Binding of Organometallic Ruthenium(II) and Osmium(II) Complexes to an Oligonucleotide: A Combined Mass Spectrometric and Theoretical Study†

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Is the Aromatic Fragment of Piano-Stool Ruthenium Compounds an Essential Feature for Anticancer Activity? The Development of New RuII-[9]aneS3 Analogues

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Inductively coupled plasma mass spectrometry to identify protein drug targets from whole cell systemsElectronic supplementary information (ESI) available: full details of laser ablation ICP-MS and QTOF operating conditions, further experimental detai

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis and characterisation of some water soluble ruthenium(II)–arene complexes and an investigation of their antibiotic and antiviral properties

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Synthesis, Characterization, and in Vitro Evaluation of Novel Ruthenium(II) η6-Arene Imidazole Complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.200600723

7 January 2021

https://api.crossref.org/works/10.1002%2FEJIC.200600723

1 reference

7 January 2021